肠道中性粒细胞胞外诱捕网促进肠屏障损伤,加重内毒素血症、全身炎症及2型糖尿病视网膜病变进展
在58例2型糖尿病患者的队列中,糖尿病视网膜病变和糖尿病黄斑水肿的严重程度与外周中性粒细胞增多、肠屏障功能障碍及内毒素血症相关;在db/db小鼠中,肠道中性粒细胞胞外诱捕网(NETosis)与肠屏障完整性丧失相关,使用PAD4抑制剂GSK484抑制NETosis可减轻肠道衰老、减缓糖尿病视网膜病变进展。
要点
- 糖尿病视网膜病变和糖尿病黄斑水肿患者存在外周中性粒细胞增多,并伴有肠通透性标志物升高。
- db/db小鼠肠道NETosis升高与肠屏障完整性丧失相关。
- PAD4抑制剂GSK484减少肠道和血液中未成熟中性粒细胞,使中性粒细胞滞留于骨髓,减缓糖尿病视网膜病变进展。
核心结论
- 糖尿病视网膜病变和糖尿病黄斑水肿的严重程度与人外周中性粒细胞增多、肠屏障功能障碍及内毒素血症相关。
- db/db小鼠肠道中性粒细胞增多(特别是干样前中性粒细胞)与NETosis升高及血管修复细胞减少相关。
- 在db/db小鼠中慢性抑制NETosis可减少肠道衰老和视网膜NETs,与内毒素血症降低及抗炎骨髓微环境相关。
研究设计与样本
- 研究纳入58例2型糖尿病患者,视网膜病变和糖尿病黄斑水肿严重程度不一,用流式细胞术检测循环中性粒细胞丰度,用血浆ELISA检测肠通透性和内毒素血症标志物。
- 使用2型糖尿病小鼠模型(db/db小鼠),观察糖尿病对肠道、血液和骨髓中性粒细胞丰度与功能、肠屏障完整性、内毒素血症及糖尿病视网膜病变严重程度的影响。
- 通过腹腔注射肽酰精氨酸脱亚胺酶4抑制剂(PAD4i)GSK484,在2型糖尿病6至7个月之间每日给药持续4周,实现NETosis的药理学抑制。
主要发现
- 在人类参与者中,中性粒细胞增多仅见于伴有糖尿病视网膜病变和糖尿病黄斑水肿的2型糖尿病患者,并伴有循环肠通透性标志物升高。
- 在糖尿病晚期,db/db小鼠出现中性粒细胞增多和肠屏障功能障碍,肠道和骨髓中干样前中性粒细胞增加,造血血管修复细胞减少。
- 在db/db小鼠肠道中,肠屏障完整性丧失加重与肠道NETosis升高相关。
- 与载体处理的db/db小鼠相比,PAD4i GSK484抑制NETosis导致肠道和血液中未成熟中性粒细胞丰度降低,并使中性粒细胞滞留于骨髓。
- PAD4i减少肠道上皮衰老,并减缓糖尿病视网膜病变进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Within the small intestine, neutrophils play an integral role in preventing bacterial infection. Upon interaction with bacteria or bacteria-derived antigens, neutrophils initiate a multi-staged response of which the terminal stage is NETosis, formation of protease-decorated nuclear DNA into extracellular traps. NETosis has a great propensity to elicit ocular damage and has been associated with diabetic retinopathy and diabetic macular oedema (DME) progression. Here, we interrogate the relationship between gut barrier dysfunction, endotoxaemia and systemic and intestinal neutrophilia in diabetic retinopathy. METHODS: In a cohort of individuals with type 2 diabetes (n=58) with varying severity of diabetic retinopathy and DME, we characterised the abundance of circulating neutrophils by flow cytometry and markers of gut permeability and endotoxaemia by plasma ELISA. In a mouse model of type 2 diabetes, we examined the effects of diabetes on abundance and function of intestinal, blood and bone marrow neutrophils, gut barrier integrity, endotoxaemia and diabetic retinopathy severity. Pharmacological inhibition of NETosis was achieved by i.p. injection of the peptidyl arginine deiminase 4 inhibitor (PAD4i) GSK484 daily for 4 weeks between 6 and 7 months of type 2 diabetes. RESULTS: In human participants, neutrophilia was unique to individuals with type 2 diabetes with diabetic retinopathy and DME and was accompanied by heightened circulating markers of gut permeability. At late-stage diabetes, neutrophilia and gut barrier dysfunction were seen in db/db mice. The db/db mice exhibited an increase in stem-like pre-neutrophils in the intestine and bone marrow and a decrease in haematopoietic vascular reparative cells. In the db/db mouse intestine, enhanced loss of gut barrier integrity was associated with elevated intestinal NETosis. Inhibition of NETosis by the PAD4i GSK484 resulted in decreased abundance of premature neutrophils in the intestine and blood and resulted in neutrophil retention in the bone marrow compared with vehicle-treated db/db mice. Additionally, the PAD4i decreased senescence within the gut epithelium and yielded a slowing of diabetic retinopathy progression. CONCLUSIONS/INTERPRETATION: Severity of diabetic retinopathy and DME were associated with peripheral neutrophilia, gut barrier dysfunction and endotoxaemia in the human participants. db/db mice exhibited intestinal neutrophilia, specifically stem-like pre-neutrophils, which was associated with elevated NETosis and decreased levels of vascular reparative cells. Chronic inhibition of NETosis in db/db mice reduced intestinal senescence and NETs in the retina. These changes were associated with reduced endotoxaemia and an anti-inflammatory bone marrow milieu with retention of pre-neutrophils in the bone marrow and increased gut infiltration of myeloid angiogenic cells. Collectively, PAD-4i treatment decreased gut barrier dysfunction, restoring physiological haematopoiesis and levels of haematopoietic vascular reparative cells.
引用
- Floyd JL, Prasad R, Dupont MD, et al. Intestinal neutrophil extracellular traps promote gut barrier damage exacerbating endotoxaemia, systemic inflammation and progression of diabetic retinopathy in type 2 diabetes. Diabetologia. 2025. PMID: 39875729. doi:10.1007/s00125-024-06349-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。